SMARCB1 encodes a core SWI/SNF/BAF chromatin-remodeling subunit that supports chromatin access and transcriptional regulation
[1]. Mechanistically, SMARCB1 enables BAF-mediated enhancer activation and helps activate bivalent promoters through opposition to Polycomb repression
[2]. In malignant rhabdoid tumor models, biallelic SMARCB1 loss defines disease biology and rewires patient-specific distal enhancers linked to MYC expression
[3][4]. Compared with related BAF assemblies, SMARCB1-containing complexes preferentially occupy enhancers, whereas BRD9-containing SMARCB1-lacking complexes localize at promoters and enhancers and create a BRD9 vulnerability after SMARCB1 loss
[5]. SMARCB1 has two splice isoforms generated by alternative splicing within exon 2, producing 385- and 376-amino-acid proteins
[6]. For experimental applications, SMARCB1-deficient models support studies of enhancer regulation, Polycomb antagonism, MYC-driven oncogenic transcription, and BRD9 dependency
[2][3][5].- SMARCB1 links BAF chromatin remodeling to enhancer activation and Polycomb-opposed promoter regulation. - SMARCB1-deficient tumor models enable mechanistic studies of MYC enhancers and BRD9 vulnerability.